European contract research organisation (CRO), Optimapharm, has expanded its office network to New York, USA, and Budapest, Hungary.
Global expansion
The company holds a strong position in central and south eastern Europe and offers access to a market of more than 300 million people. Following the global trend of consolidating the CRO market, Optimapharm is positioning as a market consolidator in the region. At the begining of the year, the company acquired the Czech CRO company MKS Research. Now, Optimapharm is operating from 12 offices, including offices in 11 countries across Europe, through which it is covering activities in 18 European countries. Its New York office will manage operations across the US.
“We have already realised a number of projects in the US; however, by opening our office and strengthening our team, we wish to significantly strengthen our business development activities in the world’s biggest CRO market, to provide US clients with the advantages of conducting trials in Europe,” commented Gordana Greguric Cicak, CEO at Optimapharm. “Our continued focus on quality and expedited patient recruitment and retention has led to a 95% repeat business rate. This, combined with our strong track record and financial position, has allowed us to continue our growth in both Europe and the US.”